HAX1

HCLS1-associated protein X-1

21 patent compounds predicted against HAX1, 17 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21943538	0.59	1/20
SCHEMBL21943762	0.57	1/20
SCHEMBL21944043	0.55	1/20
SCHEMBL21943004	0.55	1/20
SCHEMBL21942995	0.53	1/20
SCHEMBL21943411	0.53	1/20
SCHEMBL14042267	0.52	1/20
SCHEMBL21943429	0.52	1/20
SCHEMBL22066328	0.51	1/20
SCHEMBL21943540	0.49	1/20
SCHEMBL21943537	0.45	1/20
SCHEMBL24016281	0.44	1/20
SCHEMBL24532074	0.42	1/20
SCHEMBL1454562	0.42	1/20
SCHEMBL17612956	0.42	1/20
SCHEMBL12399198	0.42	1/20
SCHEMBL29911712	0.40	1/20

Germline variants in HAX1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full HAX1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to HAX1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
LMX-4 for Postoperative Pain Management in Infants and Children Undergoing Penoplasty Surgery	PHASE4	COMPLETED
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis	PHASE3	COMPLETED
A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia	PHASE3	COMPLETED
A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture	PHASE3	COMPLETED
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer	PHASE2/PHASE3	RECRUITING
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis	PHASE2	COMPLETED
A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy	PHASE2	RECRUITING
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)	PHASE2	RECRUITING
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	PHASE2	RECRUITING
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors	PHASE1/PHASE2	RECRUITING
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome	PHASE2	RECRUITING
Gene Therapy for X-linked Severe Combined Immunodeficiency	PHASE1/PHASE2	COMPLETED
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer	PHASE2	RECRUITING
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC	PHASE2	RECRUITING
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors	PHASE1	UNKNOWN
A Study of HLX42 in Advanced/Metastatic Solid Tumors	PHASE1	RECRUITING
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors	PHASE1	ENROLLING_BY_INVITATION
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients	PHASE1	RECRUITING
Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners	nan	ACTIVE_NOT_RECRUITING
Proteomics of Primary Hyperoxaluria Type 1	nan	COMPLETED
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing	nan	RECRUITING
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Rare Kidney Stone Consortium Biobank	nan	RECRUITING
Use of miRNAs in Growth Hormone Deficiency (GHD)	nan	UNKNOWN
Clinical Evaluation of Patients With X-linked Retinoschisis	nan	COMPLETED
Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders	nan	UNKNOWN
Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)	nan	UNKNOWN
Stone Disease in Children and Their Families	nan	COMPLETED
Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HAX1 binder may also engage these)

Protein	Name	Similarity
Q2KIE2	—	1.000	Q2KIE2 →
O35387	—	0.998	O35387 →
Q7TSE9	—	0.998	Q7TSE9 →
Q9QWV4	—	0.969	Q9QWV4 →
Q32KY3	—	0.962	Q32KY3 →
Q5R4T3	—	0.961	Q5R4T3 →
P58340	—	0.960	P58340 →
Q8BPM6	—	0.959	Q8BPM6 →
Q9PUU8	—	0.959	Q9PUU8 →
B2RX88	—	0.959	B2RX88 →
Q7Z5B4	—	0.959	Q7Z5B4 →
Q16626	—	0.958	Q16626 →
Q5R491	—	0.958	Q5R491 →
Q3TVI8	—	0.958	Q3TVI8 →
Q9UBU3	—	0.957	Q9UBU3 →
A2VD12	—	0.957	A2VD12 →
Q6BEG7	—	0.957	Q6BEG7 →
O70367	—	0.957	O70367 →
Q5T124	—	0.957	Q5T124 →
Q2TJA6	—	0.957	Q2TJA6 →
Q503U3	—	0.957	Q503U3 →
Q9NKV0	—	0.957	Q9NKV0 →
Q8QZV2	—	0.957	Q8QZV2 →
A0A804C8T0	—	0.957	A0A804C8T0 →
O08623	—	0.957	O08623 →
A0A7P0TBJ1	—	0.957	A0A7P0TBJ1 →
SARAF	Store-operated calcium entry-associated regulatory factor	0.957	landscape →
Q9QYH7	—	0.956	Q9QYH7 →
Q9CRD4	—	0.956	Q9CRD4 →
A0MLS4	—	0.956	A0MLS4 →